The small peptide TMTP1 (NVVRQ) has been proved to target a series of highly metastatic tumor cells. The aim of this study was to develop a new agent based on TMTP1 conjugated with Evans blue (EB), to increase tumor uptake and modify the pharmacokinetic characteristics of the resulting radiolabeled agent.
DOTA-EB-TMTP1 was prepared through conventional solid-phase peptide synthesis chemistry. Then, it was successfully labeled with Cu-64 to obtain [64Cu]DOTA-EB-TMTP1. The tumor targeting properties were evaluated in vivo using 143B xenografts.
DOTA-EB-TMTP1 was successfully labeled with Cu-64 in a yield of 87.3 ± 5.2 %. In a small animal positron emission tomography/X-ray computed tomography (PET/CT) study in osteosarcoma 143B xenograft mice, [64Cu]DOTA-EB-TMTP1 was found to rapidly accumulate in the tumor tissue. The tumor uptake increased over time and reached a plateau of 6.50 ± 0.88 % ID/g 8 h after tail vein injection. The radioactivity remained in the tumor tissue 48 h postinjection with a negligible decrease.
Overall, the introduction of the EB motif to TMTP1 significantly changed its pharmacokinetics in vivo, and this strategy fulfills the purpose of prolonging the blood circulation and enhancing the tumor uptake. [64Cu]DOTA-EB-TMTP1 is a promising agent for osteosarcoma targeting. Moreover, our study highlights that DOTA-EB-TMTP1 is a good candidate for labeling with different radionuclides for potential theranostic applications.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Harrison DJ, Geller DS, Gill JD et al (2018) Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 18:39–50
Durfee RA, Mohammed M, Luu HH (2016) Review of osteosarcoma and current management. Rheumatol Ther 3:221–243
Luetke A, Meyers PA, Lewis I, Juergens H (2014) Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev 40:523–532
Ma Z, Qin H, Chen H et al (2017) Phage display-derived oligopeptide-functionalized probes for in vivo specific photoacoustic imaging of osteosarcoma. Nanomedicine 13:111–121
Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, Shinohara ET, Bridge JA, Loeb DM, Borinstein SC, Isakoff MS (2017) Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer 123:2206–2218
Lau JL, Dunn MK (2018) Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem 26:2700–2707
Yang W, Luo D, Wang S et al (2008) TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res 14:5494–5502
Li Y, Zhang D, Shi Y, Guo Z, Wu X, Ren JL, Zhang X, Wu H (2016) Syntheses and preliminary evaluation of [18F]AlF-NOTA-G-TMTP1 for PET imaging of high aggressive hepatocellular carcinoma. Contrast Media Mol Imaging 11:262–271
Jacobson O, Kiesewetter DO, Chen X (2016) Albumin-binding Evans blue derivatives for diagnostic imaging and production of long-acting therapeutics. Bioconjug Chem 27:2239–2247
Liu Z, Chen X (2016) Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem Soc Rev 45:1432–1456
Niu G, Lang L, Kiesewetter DO et al (2014) In vivo labeling of serum albumin for PET. J Nucl Med 55:1150–1156
Chen H, Wang G, Lang L et al (2016) Chemical conjugation of Evans blue derivative: a strategy to develop long-acting therapeutics through albumin binding. Theranostics 6:243–253
Wang Z, Tian R, Niu G et al (2018) Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors. Bioconjug Chem 29:3213–3221
Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, Li F, Jacobson O, Niu G, Zhu Z, Chen X (2019) First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 46:148–158
Brandt M, Cardinale J, Aulsebrook ML et al (2018) An overview of PET radiochemistry, part 2: radiometals. J Nucl Med 59:1500–1506
Follacchio GA, De Feo MS, De Vincentis G et al (2018) Radiopharmaceuticals labelled with copper radionuclides: clinical results in human beings. Curr Radiopharm 11:22–33
Bishop MW, Janeway KA, Gorlick R (2016) Future directions in the treatment of osteosarcoma. Curr Opin Pediatr 28:26–33
Xiao M, Hong Z, Sun L et al (2011) TMTP1, a novel tumor-homing peptide, specifically targets hematological malignancies and their metastases. J Huazhong Univ Sci Technolog Med Sci 31:608–613
Hooper NM, Lendeckel U (eds) (2004) Aminopeptidases in Biology and Disease. Springer, New York
Ma X, Lv P, Ye S et al (2013) DT390-triTMTP1, a novel fusion protein of diphtheria toxin with tandem repeat TMTP1 peptide, preferentially targets metastatic tumors. Mol Pharm 10:115–126
Liu R, Ma X, Wang H et al (2014) The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases. J Mol Med (Berl) 92:165–175
Ma X, Xi L, Luo D et al (2012) Anti-tumor effects of the peptide TMTP1-GG-D(KLAKLAK)(2) on highly metastatic cancers. PLoS One 7:e42685
Li F, Cheng T, Dong Q, Wei R, Zhang Z, Luo D, Ma X, Wang S, Gao Q, Ma D, Zhu X, Xi L (2015) Evaluation of 99mTc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT. Nucl Med Biol 42:256–262
Zhou Y, Guiying J, Wang W et al (2018) A novel near-infrared fluorescent probe TMTP1-PEG4-ICG for in vivo tumor imaging. Bioconjug Chem. https://doi.org/10.1021/acs.bioconjchem.8b00756
Kleynhans J, Grobler AF, Ebenhan T, Sathekge MM, Zeevaart JR (2018) Radiopharmaceutical enhancement by drug delivery systems: a review. J Control Release 287:177–193
Jevsevar S, Kunstelj M, Porekar VG (2010) PEGylation of therapeutic proteins. Biotechnol J 5:113–128
Zhang F, Liu MR, Wan HT (2014) Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biol Pharm Bull 37:335–339
Yao L, Xue X, Yu P et al (2018) Evans blue dye: a revisit of its applications in biomedicine. Contrast Media Mol Imaging 2018:7628037
Tsopelas C, Sutton R (2002) Why certain dyes are useful for localizing the sentinel lymph node. J Nucl Med 43:1377–1382
Ahmedova A, Todorov B, Burdzhiev N, Goze C (2018) Copper radiopharmaceuticals for theranostic applications. Eur J Med Chem 157:1406–1425
Gutfilen B, Souza SA, Valentini G (2018) Copper-64: a real theranostic agent. Drug Des Dev Ther 12:3235–3245
Boswell CA, Sun X, Niu W et al (2004) Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 47:1465–1474
Sun X, Wuest M, Weisman GR et al (2002) Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem 45:469–477
Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC, Hoffman TJ, Sieckman GL, Figueroa SD, Smith CJ (2007) [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 104:12462–12467
Yesen Li was funded by the China Scholarship Council (CSC). We thank Drs. Yanjiang Han, Bulin Du, and Frezghi G. Habte for their assistance in the imaging study.
This study was funded by the National Natural Science Foundation of China (81701762) and Natural Science Foundation of Fujian Province of China (No. 2016J01642). Funding support was provided in part by the Stanford University, Department of Radiology.
Conflict of Interest
The authors declare that they have no conflict of interest.
All animal procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals (Xiamen University Institutional Animal Care and Use Committee).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Li, Y., Li, D., Wu, H. et al. Synthesis and Application of a Long-Circulating Radiolabeled Peptide for Targeting of Osteosarcoma. Mol Imaging Biol (2020). https://doi.org/10.1007/s11307-019-01468-6
- Evans blue